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Abstract
Background: We aimed to investigate the long-term effect of metformin on the blood glucose control in
non-obese patients with type 2 diabetes mellitus.
Methods: A retrospective study was performed in 213 patients with type 2 diabetes mellitus under the
administration of metformin for more than one year. The clinical parameters were investigated for 3 years. The
obese and non-obese individuals were defined as a body mass index (BMI) of 25 kg/m
2 or over (n = 105) and a
BMI of less than 25 kg/m
2 (n = 108), respectively.
Results: HbA1c levels were significantly decreased compared with those at the baseline time. The course of HbA1c
was similar between the non-obese and the obese groups, while the dose of metformin required to control blood
glucose was significantly lower in the non-obese group than in the obese group. The reductions in HbA1c were
1.2% and 1.1% at 12 months, 0.9% and 0.9% at 24 months, and 0.8% and 1.0% at 36 months in the non-obese and
obese groups, respectively. BMI did not change during the observation periods. Approximately half of all patients
required no additional antidiabetic agents or a reduction in other treatments after the initiation of metformin in
either of the two groups.
Conclusions: The present study demonstrated the long-term beneficial effect of metformin in non-obese (BMI <
25 kg/m
2) diabetic patients. This effect appears to be maintained even after the observation period of this study,
because metformin was limited to a relatively low dose in the non-obese group and the observed worsening in
glycemic control over time can probably be attenuated by increasing the dose of metformin.
Background
Metformin, one of the biguanide agents, has been
recommended for the treatment of patients with type 2
diabetes mellitus according to the consensus algorithm
published by the European Association for the Study of
Diabetes (EASD) and American Diabetes Association
(ADA), because it is economical, induces less weight
gain and does not cause hypoglycemic attacks, in addi-
tion to its glucose-lowering effect [1]. The UK Prospec-
tive Diabetes Study (UKPDS) demonstrated that
metformin is as effective as sulfonylurea to control the
blood glucose levels of obese patients with type 2 dia-
betes mellitus. Metformin yielded a stable patient body
weight, cardiovascular protection and a better patient
survival rate compared with sulfonylurea or insulin ther-
apy [2,3]. Therefore, metformin is now accepted as the
first-line drug for the type 2 diabetic obese patients.
The body mass index (BMI) and body fat percent are
different between Asians and Caucasians. The BMI is
3-4u n i t sl o w e ri nt h eg e n e r a lp o p u l a t i o ni nA s i a n
compared to Caucasians [4]. It is similar in Japanese
diabetic patients, for example, the mean BMI was 22.9
kg/m
2 in men and 23.4 kg/m
2 in women in the Japan
Diabetes Complications Study (JDCS), which was a
nationwide multi-center prospective study of type 2 dia-
betic patients [5]. Therefore, the strategy for treating
non-obese patients is considered to be important in the
treatment of type 2 diabetes mellitus for Asians, includ-
ing Japanese. * Correspondence: ito@edogawa.or.jp
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tive for non-obese diabetic individuals, the observation
periods were relatively short, usually less than one year
[6-12]. Because the effects of oral hypoglycemic agents
(OHAs), including metformin, and insulin are gradually
reduced as the treatment periods increase [2,13], the
observation of metformin over a longer duration is
necessary.
In the current study, we aimed to investigate the long-
term effects of metformin on blood glucose control in
non-obese Japanese patients with type 2 diabetes
mellitus.
Patients and Methods
Three hundred ninety-five subjects who received metfor-
min were conducted to be eligible for this study among
1371 patients with type 2 diabetes mellitus being treated
in the Department of Diabetes, Metabolism and Kidney
Diseases of Edogawa Hospital, Tokyo, Japan between
April 2008 and March 2009 (Figure 1). Any individuals
who had stopped visiting our department by changing
the hospital or for other unspecified reasons for less than
1 year (n = 129) or who discontinued metformin within
1 year after the initiation because of side effects (n =3 0 ) ,
such as gastrointestinal symptoms and liver injury, were
excluded from this study. The patients with an uncertain
metformin treatment start date or without clinical char-
acteristics at the baseline (before initiating metformin
therapy) time were also excluded from the present series
(n = 23). Finally, a retrospective study was performed in a
population of 213 patients with type 2 diabetes mellitus
under the consecutive administration of metformin for
more than 1 year. The clinical parameters, including
BMI, HbA1c level and the history of medication were
investigated from the baseline (the initial date of metfor-
min therapy) for 3 years.
All of the indications, doses and discontinuation of
metformin were guided by each patient’sp h y s i c i a n .
Although the optimization of the treatment, such as a
dose increase of metformin, an addition/reduction of
the other OHAs and an introduction of insulin therapy,
was also judged by the chief physician, it was performed
if the HbA1c levels remained higher than 7% or less
than 5.8% for 2-3 months [14].
The obese and non-obese individuals were defined
as having a BMI ≥ 25 kg/m
2 and a BMI < 25 kg/m
2,
Figure 1 Flow diagram of the population cohort. BMI: body mass index. OHAs: oral hypoglycemic agents.
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blood pressure≥ 140mmHg and/or a diastolic blood
pressure≥90mmHg. The participants currently using
antihypertensive medications were also classified as posi-
tive for hypertension. Serum total cholesterol, LDL-
cholesterol, and HDL-cholesterol concentrations were
measured with TBA-200 FR NEO using Determiner L
TC II, Determiner L LDL-C, and Determiner L HDL-C
instruments (Kyowa Medex Co., Ltd., Tokyo, Japan).
Hyperlipidaemia was defined by serum concentrations
of total cholesterollevels ≥5.7 mmol/L, LDL-cholesterol
levels ≥ 3.6mmol/L, or as patients who were already
undergoing treatment with lipid-lowering agents. The
triglyceride concentrations were not investigated in this
study because fasting blood samples could not always be
obtained for measurements. HbA1c levels were deter-
mined with a high performance liquid chromatography
method using an automated HLC-723G7 analyzer
(Tosoh Corporation, Tokyo, Japan) and calibrated by
the Japan Diabetes Society (JDS) standard calibrators.
The eGFR was calculated using the formula reported by
Matsuo et al [15]. This equation originated from the
MDRD study group [16] arranged for Japanese indivi-
duals, and it is recommended by the Japanese Society of
Nephrology: eGFR (mL/min/1.73 m
2)=1 9 4×S c r
-1.094
× Age
-0.287 × 0.739 (if female).
Statistical analysis
An analysis of variance (ANOVA) and the c
2 test were
used for between-group comparisons of the continuous
and categorical variables, respectively. A paired t-test was
conducted to determine whether there were any differ-
ences in the dose of metformin, HbA1c levels or BMI dur-
ing the observation period compared to the baseline
values. Pearson’s univariate regression was performed to
determine whether there was any association of reduced
HbA1c with other clinical parameters. The odds ratio
(OR) and respective 95% confidence interval (95% CI)
were determined to examine the strength of the relation-
ship between the requirement of additional glucose-lower-
ing agents (OHAs or insulin) and the clinical parameters
based on a multiple logistic regression analysis. Differences
with P-values of less than 0.05 (two-tailed) were consid-
ered to be statistically significant. The statistical software
package JMP, version 8.0 (SAS Institute, Cary, NC, USA),
was used to perform all of the analyses.
Results
Table 1 shows the baseline characteristics of the study
patients. The age and the duration of diabetes mellitus
were significantly higher and longer in the non-obese
group than in the obese group. There was a greater fre-
quency of patients without any antidiabetic agents prior
to metformin administration in the obese group (31%)
than in the non-obese group (16%). The blood pressure
levels, the prevalence of hypertension and serum LDL-
cholesterol concentrations were significantly higher in
the obese patients than in the non-obese patients. The
HbA1c levels and the initial dose of metformin were not
different between the two groups.
During the observation period, HbA1c levels were sig-
nificantly decreased compared with the baseline levels
(Figure 2). The course of HbA1c was equal between the
non-obese and the obese groups. HbA1c was reduced
by 1.2% and 1.1% at 12 months, 0.9% and 0.9% at
24 months, 0.8% and 1.0% at 36 months in the non-
obese and obese groups, respectively. Although the dose
of metformin required to control the blood glucose
levels gradually increased during the observation period
(Figure 3), it was significantly lower in the non-obese
g r o u p( 5 9 8±1 3 2m g / d a ya t1 2m o n t h s ,6 1 4±1 3 8m g /
day at 24 months and 677 ± 184 mg/day at 36 months)
than in the obese group (678 ± 169 mg/day at 12
months, 696 ± 170 mg/day at 24 months and 724 ± 117
mg/day at 36 months). However, the dose of metformin
after body weight correction was significantly higher in
the non-obese group than in the obese group over the
course of the observation periods (Figure 3). The values
of BMI were not significantly different through all peri-
ods in the two groups (Figure 2).




(n = 108) (n = 105) P
Body mass index (kg/m
2) 22.7 ± 1.7 28.4 ± 2.9 <0.01
Age (years) 64 ± 7 59 ± 10 <0.01
Men (%) 49 52 0.63
Duration of diabetes mellitus (years) 12 ± 9 8 ± 7 <0.01
Current plus past smoking (%) 62 67 0.59
Current drinkers (%) 58 60 0.79
Therapeutic method for diabetes
mellitus
Diet only/OHAs/Insulin (%) 16/67/18 31/48/21 <0.01
Systolic blood pressure (mmHg) 132 ± 16 137 ± 16 0.01
Diastolic blood pressure (mmHg) 78 ± 10 81 ± 11 0.02
Hypertension (%) 61 87 <0.01
Total cholesterol (mmol/L) 5.3 ± 1.1 5.3 ± 1.1 0.71
LDL cholesterol (mmol/L) 2.9 ± 0.7 3.1 ± 0.8 <0.01
HDL cholesterol (mmol/L) 1.6 ± 0.5 1.4 ± 0.3 0.09
Hyperlipidaemia (%) 81 84 0.52
Haemoglobin A1c (%) 8.1 ± 2.0 8.1 ±1.7 0.90
Uric acid (μmol/L) 282 ± 84 302 ± 79 0.10
Serum creatinine (μmol/L) 67 ± 17 67 ± 15 0.71
Estimated GFR (mL/min/1.73 m
2) 72.6 ± 17.3 75.5 ±
17.7
0.25
Initial dose of metformin (mg/day) 556 ± 110 566 ± 116 0.49
OHAs: oral hypoglycemic agents, GFR: glomerular filtration rate
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Page 3 of 9Figure 2 Changes of HbA1c levels and body mass index in obese and non-obese patients with type 2 diabetes mellitus. Data represent
the mean ± SD. Open and closed circles represent the values in obese and non-obese individuals, respectively. * P < 0.05 and ** P < 0.01 vs. 0
M (initiation of metformin).
$ P < 0.01 vs. obese.
Figure 3 Changes in the dose of metformin and those corrected by the patient’s body weight. Data represent the mean ± SD. Open and
closed circles represent the values in obese and non-obese individuals, respectively. * P < 0.05 and ** P < 0.01 vs. 0 M (initiation of metformin).
$
P < 0.05 and
$$ P < 0.01 vs. obese.
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reduction of HbA1c are shown in Table 2. Only HbA1c
l e v e l sa tt h eb a s e l i n et i m ew e r es i g n i f i c a n t l yc o r r e l a t e d
with the reduction in each time of the observation per-
iod, although the duration of diabetes mellitus only
showed a correlation at 1 year after the initiation of
metformin.
None of the patients were omitted from the study due
to the side effects induced by metformin. Three patients
discontinued metformin because of the progression of
renal dysfunction in both obese and non-obese groups
during the observation period (Figure 1). After starting
the metformin treatment, three patients (3%) in the
non-obese group and 6 patients (6%) in the obese group
were introduced onto insulin therapy. Additional OHAs
besides metformin were required in 43 (40%) of the
non-obese and 31 (30%) of the obese patients. Forty-
eight (44%) and 50 (48%) patients required no additional
antidiabetic agents (other OHAs or insulin) or a reduc-
tion of the treatment in the non-obese and obese
groups, respectively. The other OHAs besides metfor-
min were either reduced or discontinued in 10 (9%) of
non-obese and 10 (10%) of obese patients. One (1%) of
the non-obese and 5 (5%) of the obese patients no
longer required insulin therapy. The proportion of the
changes in these treatment components was not signifi-
cantly different between the non-obese and obese
groups based on a c
2 test. Table 3 shows the odds ratio
for the requirement of additional agents (other OHAs
or insulin) in the non-obese and obese patients with
type 2 diabetes mellitus according to a logistic regres-
sion analysis adjusted by age, HbA1c at baseline and the
therapeutic method (diet = 0 and oral hypoglycemic
agents plus insulin = 1). The treatment using additional
agents was significantly more frequent in the individuals
with diet therapy alone at baseline than in those using
other glucose-lowering drugs in both non-obese and
obese patients. The use of additional agents was also
required more frequently in the patients showing high
HbA1c levels at the baseline among the obese group.
The model adjusted by the duration of diabetes mellitus,
HbA1c at baseline and the therapeutic method showed
similar statistical results (date are not shown).
Figure 4 shows the changes of HbA1c levels among the
subgroups as divided by therapeutic methods (diet only,
OHAs and insulin) at the baseline in the non-obese and
obese patients with type 2 diabetes mellitus. Although
HbA1c was significantly lower in the subgroup using
OHAs at the baseline time, the changes in HbA1c levels
during the observation period were not significantly dif-
ferent among the three subgroups in the non-obese
patients. On the other hand, HbA1c was significantly
higher in the subgroups using OHAs or insulin at 24 and
36 months in the obese patients.
To possibly minimize any interference caused by
known changes in the other OHAs or insulin during the
observation period, the changes in HbA1c levels were
compared in the patients who required no additional
antidiabetic agents or reduction in treatment between
the non-obese (n = 48) and obese groups (n = 50). The
course of HbA1c levels was not significantly different
between the two groups (Figure 5). The reduction of
HbA1c was 1.1% and 0.9% at 12 months, 1.1% and 0.8%
at 24 months, 1.2% and 1.0% at 36 months in the non-
obese and obese groups, respectively.
Discussion
This study demonstrated the long-term beneficial effect
of metformin therapy in non-obese (BMI < 25 kg/m
2)
patients with type 2 diabetes mellitus. Metformin
induced a significant reduction in the HbA1c levels in
Table 2 HbA1c reduction determinants by correlation
coefficient
1 year 2 years 3 years
rPrPrP
Sex 0.06 0.42 -0.07 0.42 -0.15 0.14
Age 0.11 0.60 -0.02 0.79 0.14 0.16
Duration of diabetes 0.24 <0.01 0.16 0.10 0.15 0.21
Body mass index -0.04 0.54 -0.04 0.61 -0.10 0.34
HbA1c at baseline -0.81 <0.01 -0.73 <0.01 -0.82 <0.01
Hypertension -0.09 0.19 -0.01 0.93 -0.01 0.91
Hyperlipidaemia -0.02 0.75 -0.04 0.65 0.23 0.47
Estimated GFR 0.03 0.69 0.04 0.63 0.04 0.67
Therapeutic method 0.13 0.07 0.17 0.10 0.11 0.27
Initial dose of metformin -0.11 0.11 0.01 0.94 -0.03 0.75
Metformin dose at 1 year -0.07 0.32 0.08 0.36 -0.01 0.86
GFR: glomerular filtration rate.
Sex (man = 1, woman = 2), therapeutic method (diet = 1, oral hypoglycemic
agents = 2, insulin = 3), hypertension (absent = 0, present = 1) and
hyperlipidaemia (absent = 0, present = 1) were replaced with a number.
Table 3 Odds ratios for the requirement of additional
agents in the non-obese and obese patients with type 2
diabetes mellitus determined by a logistic regression
analysis
Wald c
2 score OR (95% CI) P
Non-obese
Age 1.52 0.91 (0.91-1.02) 0.22
HbA1c at baseline 0.08 0.97 (0.77-1.19) 0.78
Therapeutic method 5.76 0.24 (0.07-0.74) 0.02
Obese
Age 0.32 1.01 (0.97-1.06) 0.57
HbA1c at baseline 4.27 1.31 (1.02-1.71) 0.04
Therapeutic method 5.12 0.35 (0.14-0.87) 0.02
Adjusted by age, HbA1c at the baseline, and the therapeutic method (diet,
oral hypoglycemic agents + insulin).
OR: odds ratio, CI: confidence interval.
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obese and obese subjects who needed no additional
antidiabetic agents or a reduction in other treatments
during the observation period (Figure 5). Furthermore,
similar glucose-lowering effects were obtained among
the non-obese subgroups divided by the therapeutic
methods prior to the initiation of metformin (Figure 4).
Although several studies have shown the advantage of
metformin in non-obese diabetic patients [6-12], the
observation periods were relatively short. Kaku et al.
reported that the reduction of HbA1c by metformin was
not different between 303 non-obese (0.9%, BMI < 25
kg/m
2) and 300 obese (1.0%, BMI ≥ 25 kg/m
2) Japanese
patients with type 2 diabetes mellitus according to a
prospective study for 12 months [6]. Hosokawa et al.
retrospectively showed a significant 0.79% reduction in
HbA1c levels in 58 patients with a BMI ≤ 22 kg/m
2,
0.81% in 81 patients with 22 < BMI < 25 kg/m
2,a n d
0.73% in 136 patients with 25 kg/m
2 ≤ BMI 12 months
after the initiation of metformin for type 2 diabetes mel-
litus [7]. Clarke and Campbell reported that metformin
monotherapy (n = 98) was equally effective as chlorpro-
pamide (n = 91), one of the sulfonylurea agents, on
blood glucose control without HbA1c measurements,
and that metformin was superior in the body weight
control in non-obese patients with type 2 diabetes melli-
tus according to a prospective study for 1 year [8].
Yajima et al. demonstrated the metformin administra-
tion at a dose of 500-750 mg/day to be more effective in
non-obese patients (n = 22, mean BMI was 25.6 kg/m
2)
with type 2 diabetes mellitus than in those treated at a
dose of 150-300 mg/day of acarbose, an a-glucosidase
inhibitors, in a crossover study conducted with
3-months treatment periods [9]. Lund et al. described
that the glycemic regulation was equivalent between
metformin and repaglinide, an insulin secretagogue, in a
4-month crossover trial in 96 non-obese (BMI ≤ 27 kg/
m
2) European patients with type 2 diabetes mellitus
[10]. They also reported that the effect of metformin
(n = 52) and repaglinide (n = 49) was not significantly
different when combined with insulin for the treatment
of non-obese patients, according to a randomized
Figure 4 Changes of HbA1c levels among the patient subgroups divided according to therapeutic methods prior to the initiation of
metformin in the non-obese (left) and obese (right) patients with type 2 diabetes mellitus. Data represent the mean ± SD. Closed circles,
closed squares and open squares represent the diet, oral hypoglycemic agents (OHAs) and insulin therapies, respectively. * P < 0.05 and ** P <
0.01 among three treatment groups.
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showed the glucose-lowering effect of metformin to be
very similar between the non-obese and obese patients
with type 2 diabetes mellitus according to a study cover-
ing a period ranging from 3-12 months [12]. Ong at al.
revealed that metformin was efficacious in non-obese
subjects with type 2 diabetes mellitus (n =1 3 6 )a c c o r d -
ing to a retrospective analysis of 16 years [17]. This is
the first report to show the long-term effect of metfor-
min among obese and non-obese patients with type 2
diabetes mellitus. Although the definition of non-obese
w a saB M Io fl e s st h a n3 0k g / m
2, their investigation
included 7% (n = 27) of individuals with a BMI < 25 kg/
m
2 in their study subjects.
The glucose-lowering effect of metformin might be
overestimated in the present study because the HbA1c
l e v e l sw e r eo b t a i n e df r o mp a t i e n t sw h oh a du s e dm e t -
formin for more than one year. Individuals who stopped
this treatment because of a lack of efficacy or side
effects within one year were excluded. However, this
limitation could be similar between the non-obese and
obese groups.
The effects of OHAs and insulin gradually decrease as
the treatment periods become longer [2,13]. Successive
reduction of insulin from the pancreatic b-cells in
patients with type 2 diabetes mellitus is considered to
be a major factor for this attenuation of the drug effects
[18-20]. The present study showed that a gradual
increase of the metformin was required to control blood
glucose levels during the observation period. However,
the metformin dose increase was significantly lower in
non-obese patients than in obese patients. Specifically, it
m a yb ep o s s i b l et ot r e a tn o n - o b e s ed i a b e t i cp a t i e n t s
using a lower dose of metformin compared with obese
patients. Donnelly et al.a l s or e p o r t e dt h a tm e t f o r m i n
was more effective in type 2 diabetic patients with a
lower BMI [12]. However, the dose of metformin was
higher in the non-obese patients than in the obese
patients after the body weight correction in this study
(Figure 3). It seems to be a paradox that a lower total
dose of metformin while at the same time a higher dose
corrected for body weight was found in the non-obese
patients. In the present study, the duration of diabetes
mellitus was significantly longer in the non-obese
patients than in the obese patients. Furthermore, other
glucose-lowering therapies, including OHAs and insulin
were more frequently administered to the non-obese
than to the obese patients. This underscored a poten-
tially more severe stage of disease in the non-obese
rather than in the obese patients. It is therefore possible
that the endogenous insulin secretion was more strongly
impaired in the non-obese than in the obese group,
while the insulin resistance caused by, for example, visc-
eral fat also was less in the non-obese than in the obese
subjects of the present study. Although the parameters
indicating insulin resistance and endogenous insulin
secretion, such as serum or urine C-peptide concentra-
tion, were not evaluated in this study, the lower insulin
resistance and secretion in the non-obese patients might
have caused an increase in the requirement per body
weight of metformin.
The levels of HbA1c were maintained within less than
7% during the 3-year observation period of this study.
Additional OHAs or insulin treatment was necessary in
46 (43%) non-obese and 37 (35%) obese patients. It may
also be caused by the attenuation of endogenous insulin
secretion [18-20]. However, approximately half of
patients required no addition or reduction of other
treatments after the initiation of metformin in either
group. Although the present study was not performed
using metformin monotherapy, our results clinically
demonstrated the advantage of metformin either in
combination with the other antidiabetic agents or as a
single therapy without any change in the treatment.
Metformin appears to maintain the glucose-lowering
effect even after the observation period of this study had
concluded, because the dose in the non-obese group
was limited to 677 mg at 36 months of this study. The
worsening in glycemic control over time observed in
many patients with type 2 diabetes mellitus can prob-
ably be attenuated by increasing the dose of metformin
because metformin reduces the HbA1c levels in a dose-
related manner [21]. Metformin is a tolerable drug for
patients if the dosage of the first year is completed,
because no patients were omitted from this study due to
side effects caused by metformin.
Figure 5 Changes in HbA1c levels in patients who required no
additional antidiabetic agents or a reduction in treatment. Data
represent the mean ± SD. Open and closed circles represent the
values in obese and non-obese individuals, respectively. * P < 0.05
and ** P < 0.01 vs. 0 M (initiation of metformin).
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must be considered. First, the findings are inherently
limited by an inability to eliminate the effects caused by
the other glucose-lowering agents, because our investi-
gation included patients receiving a combination therapy
of metformin and other antidiabetic drugs. It is difficult
to study the long-term course of metformin monother-
apy because of the attenuation of the effect as time
passes [2,13]. Only 11 (3 non-obese and 8 obese)
patients were treated with metformin monotherapy dur-
ing the entire period, thus making it impossible to
determine the significance of the therapy in these
patients. To possibly minimize the interference caused
by known changes in the other OHAs or insulin, the
changes in HbA1c levels were compared in the patients
who required no additional antidiabetic agents or reduc-
tion in treatment between the non-obese and obese
groups (Figure 5). Although the change in the insulin
dose is considered to be important among the patients
receiving insulin treatment at baseline, this factor was
not investigated in the present study. We therefore can-
n o te x c l u d et h ep o s s i b i l i t yt h a ts o m ed i f f e r e n c e si nt h e
need for increasing the insulin doses between the non-
obese and obese group of patients confounded our data
with respect to the efficacy of metformin treatment dur-
ing this study. This factor could also be a confounder
even in those patients with no known (other) changes in
the treatment. Second, this investigation is a retrospec-
tive study without the obvious criteria for the changes
in treatment methods. Because the optimization of the
metformin dose and the coordination of the treatment
were dependent on each patient’s physician, we consid-
ered that errors on the effects of metformin could have
occurred. Third, the present study did not include a
control group with a different treatment regimen, such
as insulin secretagogues. Therefore, it is unknown
whether the observed similarities and differences
between the non-obese and obese patients were specific
for these groups and/or specific effects of metformin
therapy. Fourth, the associations of metformin with dia-
betic vascular events were not examined in this study.
Furthermore, the risk factors for cardiovascular diseases
such as blood pressure and serum lipid profile were not
analyzed during the observation period because various
antihypertensive agents and statins were used. The
results of this study demonstrated the glucose-lowering
effect of metformin in a group of non-obese patients
with type 2 diabetes mellitus who continued such treat-
ment for at least 1 year. Therefore, investigations to
evaluate the effect of metformin therapy to potentially
reduce the risk of developing diabetic complications also
in non-obese patients with type 2 diabetes mellitus
should be considered in the future.
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